Disc Medicine Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Disc Medicine şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-8.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-8.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Jul 21

Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate

Key Insights Disc Medicine's estimated fair value is US$89.30 based on 2 Stage Free Cash Flow to Equity Disc Medicine...

Seeking Alpha • Oct 06

Disc Medicine: Achieving Functional Endpoint More Important

Summary Disc Medicine's lead molecule, bitopertin, failed to meet key functional endpoints in phase 2 trials for Erythropoietic Porphyrias, causing a significant drop in stock price. Despite reducing protoporphyrin IX levels, bitopertin did not improve sunlight tolerance, making it ineffective for EPP patients. With a market cap of $1.49bn and $500mn in cash, Disc Medicine has a cash runway of over 10 quarters but faces high risks. Given the failure of bitopertin in its lead indication, I am not interested in investing in Disc Medicine stock at this time. Read the full article on Seeking Alpha

Analiz Makalesi • Aug 13

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Jun 14

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Summary Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024. Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024. Initial pharmacokinetic and pharmacodynamic data from the phase 1 healthy volunteer study for iron overload disorders expected in Q2 of 2024. Read the full article on Seeking Alpha

Seeking Alpha • Jan 31

Disc Medicine: What's Behind The Huge Rally

Summary Disc Medicine, Inc. has seen a strong rally in its stock after positive open-label data from its lead heme biosynthesis program, bitopertin. Results from a placebo-controlled trial, expected in early 2024, will validate bitopertin's efficacy and could lead to a registrational trial in late 2024 or early 2025. Disc Medicine has a cash runway until 2026, but its domestic peak-sales potential is somewhat limited. A full investment analysis around Disc Medicine follows in the paragraphs below. Read the full article on Seeking Alpha

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: IRON şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: IRON şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Disc Medicine Piyasaya Karşı Temettü Getirisi

IRON temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (IRON)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.1%
Analist tahmini (IRON) (3 yıla kadar)	n/a

Önemli Temettü: IRON şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, IRON şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: IRON şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: IRON herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/20 01:14
Gün Sonu Hisse Fiyatı	2026/09/18 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Disc Medicine, Inc. 18 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Evan Seigerman	BMO Capital Markets Equity Research
Kristen Kluska	Cantor Fitzgerald & Co.
Douglas Tsao	H.C. Wainwright & Co.

Disc Medicine Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Disc Medicine Faces Legal Probe After FDA Letter Spurs 22% One-Day Price Drop

Independent Director exercised options and sold US$679k worth of stock

Disc Medicine Reports Phase 2 Data on DISC-3405 in Polycythemia Vera and Myelofibrosis

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

CEO, President & Director notifies of intention to sell stock

Chief Legal Officer & Secretary exercised options and sold US$327k worth of stock

Disc Medicine Aligns With FDA on Bitopertin Phase 3 Approval Path and Expands Access

Going Deeper On Disc Medicine

Chief Opearating Officer notifies of intention to sell stock

Disc Medicine Faces Securities Inquiry Over Potentially Misleading Business Information

Chief Opearating Officer notifies of intention to sell stock

Disc Medicine Stock Under Pressure After FDA Letter and Legal Investigation

Disc Medicine (IRON) Stock Could Be 64% Below Fair Value After EHA Trial Update

Disc Medicine Presents Positive Clinical Updates on Disc-0974, Bitopertin, and Disc-3405 At the 2026 European Hematology Association Annual Meeting

Disc Medicine Gains FDA Alignment on Bitopertin as Securities Probe Follows Stock Drop

Disc Medicine Presents Updated Data from RALLY-MF Phase 2 Trial of DISC-0974 in Anemia of Myelofibrosis At Asco Annual Meeting

Disc Medicine Advances With Positive Myelofibrosis Data and Expanded Access for Bitopertin

Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients

Disc Medicine, Inc., Annual General Meeting, Jun 18, 2026

Disc Medicine Announces Completion of Enrollment of Phase 3 Apollo Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine, Inc. Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

Disc Medicine Inc Appoints Lisa Amaya Price as Chief Human Resources Officer

Disc Medicine, Inc. Presents Positive Initial Data from Rally-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine, Inc. Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Disc Medicine, Inc. Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine, Inc. Announces Resignation of Mona Ashiya as Member of Board of Directors and Member of the Compensation Committee and the Nominating and Corporate Governance Committee, Effective October 3, 2025

Disc Medicine, Inc. Announces Submission of New Drug Application to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (Epp)

Disc Medicine, Inc. Announces Positive Pre-Nda Meeting and Confirms Plans to Submit Nda for Bitopertin in Epp in October 2025

Disc Medicine, Inc. Appoints Nadim Ahmed to Its Board of Directors

Disc Medicine, Inc.(NasdaqGM:IRON) dropped from Russell 2000 Value Index

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio At the European Hematology Association 2025 Annual Congress

Disc Medicine, Inc., Annual General Meeting, Jun 11, 2025

Disc Medicine, Inc. Announces That the Presentation of Full Results from Phase 2 Aurora and Beacon Studies

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $225.499982 million.

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine: Potential Promise Amid Uncertainty

Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate

Disc Medicine Presents Positive Updated Results from Phase 1B Trial in Patients with Myelofibrosis and Anemia in an Oral Presentation At the 66Th American Society of Hematology Annual Meeting

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $29.7 million.

Disc Medicine, Inc. Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine: Achieving Functional Endpoint More Important

Disc Medicine, Inc. Announces Appointment of Steve Caffé as Chief Regulatory Officer

Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $177.984 million.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria (EPP)

New major risk - Revenue and earnings growth

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Key Executive notifies of intention to sell stock

Disc Medicine: What's Behind The Huge Rally

Key Executive notifies of intention to sell stock

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Independent Director notifies of intention to sell stock

Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology (Ash) Annual Meeting

General Counsel notifies of intention to sell stock

General Counsel exercised options and sold US$176k worth of stock

General Counsel notifies of intention to sell stock

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Chief Financial Officer notifies of intention to sell stock

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association (EHA) 2023 Congress

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme